EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-world treatment patterns and outcomes of deutetrabenazine in patients with chorea associated with Huntington disease: A retrospective chart review study

Victor Sung iD, Ashley White, Hela Romdhani, Sakshi Sethi, Debbie Goldschmidt, Rajeev Ayyagari, Nayla Chaijale, Ayelet Yaari iD, Mark Forrest Gordon iD, Amy Yang, Rinat Ribalov

Journal of Huntington's Disease · 2026-11 · 15 (4) · 588-598

DOI: 10.1177/18796397261468475 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Huntington's Disease, online erschienen am 14.08.2026. Verfasst von Victor Sung und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Division of Movement Disorders, University of Alabama at Birmingham, Birmingham, AL, USA. Hauptthemen laut MEDLINE: Tetrabenazine, Huntington Disease, Adrenergic Uptake Inhibitors, Chorea. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Teva Branded Pharmaceutical Products R&D LLC..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Real-world evidence of deutetrabenazine (DTBZ) treatment for Huntington disease (HD)-associated chorea is limited.

Methods

This is a non-interventional, retrospective chart review study from a Huntington's Disease Society of America clinical practice at the University of Alabama at Birmingham (UAB). Patients had a diagnosis of HD-associated chorea, DTBZ initiation (4/2017–12/2021), ≥2 visits at UAB, and ≥3 months of chorea-related care records post DTBZ initiation. The last Unified HD Rating Scale–Total Maximal Chorea (TMC) score within 3 months prior to DTBZ initiation and first after reaching the last stable dose during follow-up were analyzed.

Results

Among 80 eligible patient charts, mean (SD) age was 52.1 (12.6) years and 45 (56.3%) were female. Fifty patients had pre- and post-DTBZ TMC scores and reached a stable dose, including 30 with no prior tetrabenazine (TBZ) or DTBZ exposure, 8 with prior TBZ exposure with a switch to DTBZ after a gap, and 9 with prior TBZ exposure with a switch to DTBZ without a gap. Mean (SD) TMC score decreased (i.e., improved) by 3.7 (4.5), 7.8 (2.8), and 2.1 (4.2), respectively. Overall, 27 (33.8%) patients had ≥1 adverse event recorded between DTBZ initiation and the first visit with a TMC score after reaching their last stable DTBZ dose or DTBZ discontinuation for those without a stable dose.

Discussion

This real-world study describes improvements in TMC scores among patients with HD-associated chorea treated with DTBZ, regardless of prior treatment. The observed safety profile supports the known safety profile of DTBZ in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TetrabenazineHuntington DiseaseAdrenergic Uptake InhibitorsChoreaHumansFemaleRetrospective StudiesMiddle AgedMaleTreatment OutcomeAdult

Stichwörter der Autor:innen

choreaclinical carehealth services outcomes researchmovement disordersprevalence

Substanzen

TetrabenazinedeutetrabenazineAdrenergic Uptake Inhibitors

Autor:innen und Institutionen

  • Department of Neurology, Division of Movement Disorders, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Analysis Group, Inc., Boston, MA, USA.
  • Global Medical Affairs, Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, USA.
  • Global Medical Affairs, Teva Pharmaceutical Industries Ltd, Tel Aviv, Israel.
  • Innovative Medicines, Global Clinical Development, Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, USA.
  • Global Health Economics and Outcomes Research, Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, USA.

ORCID-Profile: Victor Sung, Ayelet Yaari, Mark Forrest Gordon

Förderung

  • Teva Branded Pharmaceutical Products R&D LLC.

Zitieren

APA

Sung, V., White, A., Romdhani, H., Sethi, S., Goldschmidt, D., Ayyagari, R., Chaijale, N., Yaari, A., Gordon, M. F., Yang, A., & Ribalov, R. (2026). Real-world treatment patterns and outcomes of deutetrabenazine in patients with chorea associated with Huntington disease: A retrospective chart review study. Journal of Huntington's Disease, 15(4), 588-598. https://doi.org/10.1177/18796397261468475

Vancouver

Sung V, White A, Romdhani H, Sethi S, Goldschmidt D, Ayyagari R, et al. Real-world treatment patterns and outcomes of deutetrabenazine in patients with chorea associated with Huntington disease: A retrospective chart review study. Journal of Huntington's Disease. 2026;15(4):588-598. doi:10.1177/18796397261468475

BibTeX
@article{Sung2026,
  author = {Sung, Victor and White, Ashley and Romdhani, Hela and Sethi, Sakshi and Goldschmidt, Debbie and Ayyagari, Rajeev and Chaijale, Nayla and Yaari, Ayelet and Gordon, Mark Forrest and Yang, Amy and Ribalov, Rinat},
  title = {Real-world treatment patterns and outcomes of deutetrabenazine in patients with chorea associated with Huntington disease: A retrospective chart review study},
  journal = {Journal of Huntington's Disease},
  year = {2026},
  volume = {15},
  number = {4},
  pages = {588--598},
  doi = {10.1177/18796397261468475}
}
Kostenlos starten →